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Abstract
Background: Lyme disease, caused by Borrelia burgdorferi, is the most common tick-borne infection in the United
States. Although humans can be infected by at least 16 different strains of B. burgdorferi, the overwhelming majority
of infections are due to only four strains. It was recently demonstrated that patients who are treated for early Lyme
disease develop immunity to the specific strain of B. burgdorferi that caused their infection. The aim of this study is
to estimate the reduction in cases of Lyme disease in the United States that may occur as a result of type specific
immunity.
Methods: The analysis was performed based on three analytical models that assessed the effects of type specific
immunity. Observational data on the frequency with which different B. burgdorferi strains cause human infection in
culture-confirmed patients with an initial episode of erythema migrans diagnosed between 1991 and 2005 in the
Northeastern United States were used in the analyses.
Results: Assuming a reinfection rate of 3 % and a total incidence of Lyme disease per year of 300,000, the estimated
number of averted cases of Lyme disease per year ranges from 319 to 2378 depending on the duration of type specific
immunity and the model used.
Conclusion: Given the assumptions of the analyses, this analysis suggests that type specific immunity is likely to have
public health significance in the United States.
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Background
Lyme disease, caused by Borrelia burgdorferi, is the most
common tick-borne infection in the United States. Add-
itionally, recent evidence suggests that the 30,000 re-
ported cases actually represent only 10 % of the true
incidence in the United States [1]. The majority of re-
ported Lyme disease cases originate in the Northeastern
(82 %) and Midwest (9 %) United States [2], although
the geographic range is currently expanding [3–5]. Des-
pite the fact that more than 16 B. burgdorferi lineages
exist in these areas, the majority of disseminated human
infections are caused by just four. Similarly, the subsets
of B. burgdorferi lineages that cause infection in wild an-
imals vary among animal species [6–8].
B. burgdorferi lineages have been categorized by their al-
lele at the highly variable outer surface protein C (ospC)
locus, and are often referred to by their ospC genotype.
While there is ample evidence that the surface exposed
OspC lipoprotein is necessary for infection, and that there
is a strong and protective immune response against OspC
[9–11], there is currently limited direct evidence that the
variability at ospC directly affects differential infectivity of
humans or other animal species. Nevertheless, the vari-
ability at the ospC locus, along with the high linkage
among all genetic loci [12–15], makes ospC a good marker
to delineate different B. burgdorferi lineages.
Based on a unique data set of culture-confirmed initial
and repeat episodes of early Lyme in antibiotic-treated
patients with erythema migrans, two conclusions were
made. One was that recurrence of early Lyme disease in
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such patients is due to reinfections rather than relapses
of the original infection [16]. Secondly, based on mul-
tiple modeling techniques and using observed data on
the frequency with which different strains of B. burgdor-
feri were cultured from initial versus recurrent episodes
of early Lyme disease, it was demonstrated that type spe-
cific immunity lasting at least five years is likely to de-
velop following infection [17].
In this analysis, we attempt to estimate the reduction
in cases of Lyme disease that may occur as a result of
the recently demonstrated type specific immunity. The
analyses suggest that the presence of type specific im-
munity is likely to have public health significance.
Methods
Several assumptions were made to perform the analyses.
The probability of exposure to various strains of B. burg-
dorferi due to a bite from an infected tick was estimated
based on the frequency with which different strains of B.
burgdorferi were recovered from skin biopsy samples of
patients with early Lyme disease associated with ery-
thema migrans in the Lower Hudson Valley region of
New York State (Table 1) [17, 18]. These published data
were derived from the distribution of strains cultured
from the skin of a sample of 200 patients (from a total
of 298) with no prior history of Lyme disease that were
diagnosed between 1991 and 2005, as described previ-
ously [17, 18]. B. burgdorferi lineages were previously
classified according to the allele at the ospC gene as pre-
viously described e.g., [15, 18, 19]. The present analysis
was performed in 2014 and is exempted from Institu-
tional Review Board (IRB) approval as it involved the
analyses of existing published data (category 4), as de-
fined by the Office for Human Research Protections
(www.hhs.gov/ohrp/).
Additional assumptions that were made included that
type specific immunity follows infection with all strains
of B. burgdorferi and is absolute, lasts ≥ 5 years, and is
restricted to a single OspC genotype. Based on our prior
observations we assumed that 3 % of Lyme disease cases
are due to reinfections, but also assessed the impact of
type specific immunity if 1 % or 5 % of infections occur
as a result of a reinfection.
Number of B. burgdorferi infections averted due to strain
specific immunity
The potential impact that strain-specific immunity could
have on human Lyme disease incidence was assessed
using three different mathematical modeling structures.
Analytical models are necessary to estimate what would
have occurred in the absence of a factor such as strain-
specific immunity, a process known as precluding. The
models employed account for the total number of hu-
man cases as well as the number of averted cases. In this
study, the term “averted cases” refers to cases that would
have occurred in the absence of strain-specific immun-
ity, holding all other model variables constant.
The three analytical models have different underlying
assumptions, different sets of limitations, and different
degrees of realism, and are thus useful to assess varying
aspects of the effects of strain-specific immunity
(Table 2).
Deterministic probability model
With the deterministic probability model the proportion
of human cases that are averted due to strain-specific
immunity is equivalent to the proportion of patients that
are exposed to a B. burgdorferi strain with which the pa-
tient has been previously infected. This proportion can
be calculated as
A¼Σf i2
where fi is the frequency of the i
th strain (Table 1) and A
is the proportion of cases averted due to strain-specific
immunity; eg., the proportion of patients that are ex-
posed to strain K on two separate occasions occurs at a
frequency of fK
2 = 0.3652 = 0.1332 (Table 1). Based on the
~30,000 Lyme disease reported cases in the United
States and an estimated 3 % reinfection rate the number
of averted cases can be calculated as
Table 1 Frequency of the different OspC types that were
cultured from the skin of 200 patients with erythema migrans
[17, 18].
OspC type Number (%)
Total 200 (100 %)
K 73 (36.5 %)
A 38 (19 %)
B 28 (14 %)
I 14 (7 %)
N 13 (6.5 %)
E 13 (6.5 %)
U 9 (4.5 %)
H 5 (2.5 %)
C 2 (1 %)
D 2 (1 %)
F 1 (0.5 %)
G 1 (0.5 %)
M 1 (0.5 %)
J 0 (0 %)
L 0 (0 %)
T 0 (0 %)
Bold font indicates invasive OspC types, comprising 76.5 % of the total cases
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N ¼ 0:03 Að Þ= 1 − Að Þ  30; 000
where N is the total number of cases averted in relation-
ship to the total number of cases in the United States.
Equilibrium dynamic model
In the equilibrium dynamic model, humans can change
from susceptible (S) to infected (I) to immune (R) and
back to susceptible (S). The effect of strain-specific im-
munity on human Lyme disease incidence is the sum of
number of averted cases from exposure to each individ-
ual B. burgdorferi strain.
Patients transition from susceptible to strain i (Si) to
infected by strain i (Ii) at rate βi, equivalent to the inci-
dence rate of strain i.
Ii¼βi Si
The incidence rate for each strain i is scaled to the
total incidence rate for all B. burgdorferi strains using
the frequency at which each strain is found in human in-
fections such that
β ¼ Σ βi
Patients transition from the infected state (Ii) to the
immune state (Ri) at a rate of 1, such that the transition
occurs with each iteration of the model (1 year) with
100 % probability. Patients are assumed to transition
from the immune state (Ri) back to the susceptible state
(Si) in either 5 years (γ = 0.2) or 30 years (γ = 0.0333).
These 2 limits were selected based on prior estimates of
the minimum duration of strain specific immunity [17]
or a maximum approximating life-long immunity.
Therefore, the number of averted cases of Lyme disease
can be estimated as the number of individuals in the in-
fected or immune states (Ii + Ri) that are exposed to
strain i.
A ¼ βi  Ii þ Rið Þ
where A is the number of averted cases as a function of
the incidence rate of Lyme disease (βi).
Individual-based stochastic simulation model
In the stochastic simulation model, we simulated
100,000 individuals over a 30 year period in which they
could be exposed to an infectious tick bite. Each individ-
ual has a set per year probability of exposure to an infec-
tious tick bite which is drawn from an exponential
frequency distribution such that most individuals have a
very low per year probability of exposure. The rate par-
ameter of the exponential distribution was chosen such
that the reinfection rate would equal 3 % of total infec-
tions at an incidence rate of 100 cases of Lyme disease
per 100,000 people.
In each year that an individual is available to be ex-
posed to an infectious tick bite, the simulation deter-
mines if the individual is exposed to an infectious tick
bite given the per year probability of exposure of the
simulated individual and a random number generator. If
the individual is exposed to an infectious tick bite, the
probability of exposure to a particular borrelial strain
was assumed to equal the frequency at which that strain
has been recovered from patients (Table 1). If the simu-
lated individual has been infected by the chosen strain
Table 2 Summary of the characteristics of the three models used to estimate the number of averted cases of Lyme disease due to
type specific immunity
Model Key assumptionsa Benefits Limitations
Deterministic probability Lyme disease patients’ probability of
exposure to infectious bite similar to
general population.
Extremely simple and flexible. Allows a separate
analysis focusing on infections caused by invasive
strains of B. burgdorferi.
May over estimate the
impact of immunity on
averted cases.
Immunity is permanent. Provides the upper limit of averted cases.
Equilibrium dynamic Lyme disease patients’ probability of
exposure to infectious bite similar to
general population.
Simple. May under estimate the
impact of immunity on
averted cases.Provides the lower limit of averted cases.
Immunity lasts 5 to 30 years.
Lyme disease patients are at risk for tick
bites for 30 years.
Individual-based
stochastic
Lyme disease patients’ probability of
exposure to infectious bite higher than in
general population.




May provide the most realistic estimate of the
number of averted cases.Immunity lasts 5 to 30 years.
Patients are at risk for tick bites for
30 years.
aall models share the key assumptions that immunity provides 100 % protection to a particular OspC type of B. burgdorferi, that there is no cross-immunity across
different OspC types, and that in the absence of immunity the likelihood of developing infection with a particular OspC type follows the strain frequencies presented
in Table 1
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within the time frame of strain-specific immunity, the
individual is considered immune and an averted case is
recorded. If the individual has not been previously in-
fected or if the duration of strain-specific immunity has
ended, an infection with the chosen strain is recorded.
The simulation records the number of averted and suc-
cessful infections among 100,000 simulated individuals.
For every combination of parameters, 200 simulations
were run each with 100,000 individuals. Parameters in-
cluded varying duration of strain-specific immunity (5 or
30 years) and varying incidence rates of Lyme disease
(0–500 per 100,000 people).
Results
If the reinfection rate is 3 % and the total number of
Lyme cases per year is 300,000, the estimated number of
averted cases of Lyme disease per year ranges from 319
to 2,378 depending on the model employed and the par-
ticular assumptions used for that model (Table 3). With
different assumptions on the incidence of Lyme disease
and on the frequency of reinfections, however, the num-
ber of averted cases per year might be as few as 11 or as
many as 4,100 (Table 3 and Additional file 1: Figure S1).
Available published data suggest that 83.3 % of pa-
tients with blood culture-confirmed disseminated B.
burgdorferi infection from the Lower Hudson Valley re-
gion of New York State are infected with one of just four
OspC genotypes: A (accounted for 23.5 % of positive
blood cultures), B (for 14.4 %), I (for 12.1 %) or K (for
33.3 %) [18]. Assuming that a patient was initially in-
fected by one of these four strains and that patients are
exposed to B. burgdorferi strains at rates consistent with
published data on initial human infections (Table 1,
Additional file 2: Table S1), the results of the determinis-
tic model suggest that the probability of a positive blood
culture in patients with a recurrence of erythema
migrans would be reduced by approximately 25 % due to
strain-specific immunity.
Discussion
The number of cases of Lyme disease in the United
States continues to rise over time and expand geograph-
ically [3, 5]. Prevention methods rely primarily on mea-
sures to avoid tick bites, which have had variable rates of
adherence and success [20]. Unfortunately, no vaccine to
prevent B. burgdorferi infections is currently available
for humans.
The results of this study suggest, given the assumptions
of an annual 3 % reinfection rate and 300,000 total cases
per year, that were it not for the presence of type specific
immunity there might be as many as 2,300 additional
cases of Lyme disease per year in the United States. Al-
though only recently recognized [17], the presence of type
specific immunity to strains of B. burgdorferi is therefore
likely to have public health significance. Furthermore, the
frequency of Lyme disease cases with hematogenous dis-
semination of the spirochete would also be appreciably
higher in the absence of type specific immunity. Our
Table 3 Estimation of the yearly number of averted Lyme diseases cases in the United States based on the number of Lyme disease
cases reported (approximately 30,000) or estimated (around 300,000) using three different analyses. The number of averted cases
was calculated using three different estimates of reinfection rates: 1 %, 3 %, and 5 %
Lyme disease incidence Immunity length Estimated number of averted cases
Deterministic probability modela
1 % reinfection 3 % reinfection 5 % reinfection
30,000 cases life span 77 232 387
300,000 cases life span 775 2,324 3,873
Equilibrium dynamic model
1 % reinfection 3 % reinfection 5 % reinfection
30,000 cases 5 years 11 32 53
30,000 cases 30 years 78 233 390
300,000 cases 5 years 106 319 532
300,000 cases 30 years 776 2,333 3,898
Individual-based stochastic model
1 % reinfection 3 % reinfection 5 % reinfection
30,000 cases 5 years 23 55 80
30,000 cases 30 years 90 238 410
300,000 cases 5 years 227 549 799
300,000 cases 30 years 899 2,378 4,100
aCalculations based on the values in Table 1
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findings suggest a 25 % risk reduction in having a positive
blood culture during a recurrence if the initial infection
was caused by one the four genotypes most often associ-
ated with detectable spirochetemia. In a previously pub-
lished study the frequency of a positive blood culture for
B. burgdorferi in 41 patients with a prior history of Lyme
disease was 31.7 % versus 46.5 % in 172 patients during a
first episode of Lyme disease [18]. Thus, the observed
31.5 % reduction in the rate of positive blood cultures in
patients with prior Lyme disease in that study is consistent
with the existence and clinical relevance of type specific
immunity.
The public health effects of type specific immunity
have been previously observed with several pathogens.
For example, patients infected with one variety of the in-
fluenza virus are protected from reinfection with the
same strain, but remain susceptible to other strains. The
public health effect of type specific immunity in human
influenza has temporal limitations due to the rapid evo-
lution of novel strains [21], which is not apparent in B.
burgdorferi populations.
Limitations of our study center around the accuracy of
several key assumptions: that Table 1 reflects the overall
frequency of infection by different strains of B. burgdor-
feri in the United States, that type specific immunity is
restricted to just a single genotype, and that type specific
immunity is 100 % protective for that genotype. The re-
ported frequencies at which humans are exposed to each
B. burgdorferi strain (Table 1) may be inaccurate due to
geographic variation in the frequencies of strains in ticks
and due to differences in cultivability among strains.
The frequencies of B. burgdorferi strains in ticks differs
among northeastern, Midwestern, and California Lyme
disease foci e.g.,[6, 15, 22, 23] implying that human ex-
posure rates differ [24]. These differences would alter
the calculations of the public health effect of type spe-
cific immunity for the 18 % of infections that occur out-
side of the northeastern foci [2], although it is difficult
to predict if the calculated number of averted cases
would increase or decrease from those reported here.
Inaccuracies in the reported frequencies at which
humans are exposed to each B. burgdorferi strain
(Table 1) may also be caused by culture biases. How-
ever, several lines of evidence suggest that it is un-
likely that culture bias has resulted in the uneven
detection of strains in human blood. First, there are
differences in the frequencies of strains in cultures of
skin versus blood of humans. Second, non-culture
methodologies performed with various animal species
produce similar types of frequency biases, suggesting
that the biases are not the result of differences in cul-
tivability. In addition to culture biases, we did not
consider in the analyses that ticks may transmit more
than one strain of B. burgdorferi simultaneously [6, 19],
and thus even if the person bitten was immune to reinfec-
tion by one of the transmitted strains, that individual
might still develop Lyme disease from the other transmit-
ted strain(s).
The accuracy of the assessment of the public health
impact of type specific immunity is also impacted by the
assumption that type specific immunity is restricted to
just a single genotype and that it is 100 % protective for
that genotype. The analyses assumed that each strain
elicited a protective response against infections with the
same strain but afforded no cross protection for other
strains. It is possible that partial or full protective im-
munity also develops against additional strains [25],
which would elevate the estimate of the public health ef-
fect of this type of immunity. The analyses also assumed
100 % protection from reinfection. Relaxing this as-
sumption would decrease the estimate of the public
health impact of type specific immunity. Experimental
infections or data sets with larger numbers of patients
with recurrent infections are necessary to determine the
extent of cross immunity among strains and the degree
of protection.
Although none of these assumptions is likely to be
completely accurate, making a precise estimate of the
impact of type specific immunity impossible to deter-
mine, it is reasonable to conclude that the presence
of some degree of type specific immunity should
serve to reduce the number of recurrent infections.
In addition, the impact of immunity on Lyme disease
prevention is likely to be higher than we have esti-
mated, since the immune response associated with
later manifestations of Lyme disease, such as Lyme
arthritis, was not considered in this analysis and is
likely to be broader and longer lasting than would
occur following erythema migrans [26].
The molecular mechanisms leading to type specific
immunity in B. burgdorferi are not known. Immune
responses targeting OspC have been the focus of con-
siderable research, but evidence to support the hy-
pothesis that an immune response to OspC is
responsible for type specific immunity is indirect. For
example, transient immunity to reinfection with the
same strain of B. burgdorferi has been demonstrated
in laboratory animals and mice immunized with one
OspC protein are selectively protected against infec-
tion with only B. burgdorferi expressing the same
OspC protein, not against strains expressing a differ-
ent OspC protein [27, 28]. Strain-specific immunity is
unlikely to be restricted to OspC and may develop
against multiple B. burgdorferi strain-specific proteins
that are in genetic linkage with OspC e.g., [13, 19, 29].
Further empirical studies that characterize multiple anti-
gens are necessary to determine what antigens are respon-
sible for strain-specific immunity.
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Conclusion
Recent data have demonstrated the development of
type specific immunity against the infecting strain of
B. burgdorferi in patients treated for early Lyme dis-
ease. The current analysis suggests that this observa-
tion is likely to have public health significance.
Additional files
Additional file 1: Figure S1. The proportion of cases occurring in
patients with a prior infection and the proportion of averted cases
increases exponentially with higher incidence rates in both the equilibrium
dynamic (left column, panels A, C) and individual stochastic models (right
column, panels B, D). The proportion of reinfections that are averted due to
strain-specific immunity (bottom row, panels E, F) is constant across incidence
rates in both models. The dashed lines describe the data output when
strain-specific immunity is assumed to last 5 years; the black lines describe
the data output when strain-specific immunity is assumed to last 30 years.
(DOC 311 kb)
Additional file 2: Table S1. Frequency of the different OspC types that
were cultured from the skin of 200 patients with erythema migrans (17, 18)
and expected percentage increase in total reinfections due to particular OspC
types, if there were no strain specific immunity based on the deterministic
probability model. Bold font indicates invasive OspC types, comprising 76.5 %
of the total cases. (DOC 35 kb)
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